Health and Fitness Health and Fitness
Wed, April 17, 2013
[ Wed, Apr 17th 2013 ] - Market Wire
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
[ Wed, Apr 17th 2013 ] - Market Wire
Solta Medical to Report First Quarter 2013 Results and Host Conference Call on May 1, 2013
[ Wed, Apr 17th 2013 ] - Market Wire
FDA Advisory Committee Recommends Approval of BREO(TM) ELLIPTA(TM) for the Treatment of COPD
[ Wed, Apr 17th 2013 ] - Market Wire
STAAR Surgical Celebrates Over 350,000 Successful .. CLa" Implants at ASCRS Symposium in San Francisco
[ Wed, Apr 17th 2013 ] - Market Wire
NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013
[ Wed, Apr 17th 2013 ] - Market Wire
Nephros Announces Rights Offering and Temporary R .. duction in Exercise Price for March 2011 Warrants
[ Wed, Apr 17th 2013 ] - Market Wire
Critical Alerts For Merck, NetApp, CSX, Theravance, and Uni-Pixel Released By InvestorsObserver
[ Wed, Apr 17th 2013 ] - Market Wire
BIOLASE Enters Into Agreement for Lambda S.p.A. to Pay Royalties
[ Wed, Apr 17th 2013 ] - Market Wire
Randy Hill Appointed to Vasomedical Board of Directors
[ Wed, Apr 17th 2013 ] - Market Wire
U.S. Army and Vermillion to Assess Health and Economic Benefits of OVA1 as a Standard of Care
[ Wed, Apr 17th 2013 ] - Market Wire
SafeCode Drug Technologies to Hire Project Manage .. to Market FDA Approved Painless Injection Device
[ Wed, Apr 17th 2013 ] - Market Wire
Nearly 8 Million Healthcare Personnel Come in Contact with Chemotherapy Drugs, According to CDC
[ Wed, Apr 17th 2013 ] - Market Wire
Cantel Medical To Present At Needham 12th Annual Healthcare Conference
[ Wed, Apr 17th 2013 ] - Market Wire
InterMune To Release First Quarter Financial Results On April 24
[ Wed, Apr 17th 2013 ] - Market Wire
Arena Pharma, Celgene, Incyte, Spectrum Pharma, and Geron Under StockCall's Microscope
[ Wed, Apr 17th 2013 ] - Market Wire
Trading in Theravance Common Stock Halted
[ Wed, Apr 17th 2013 ] - Market Wire
Omeros Files Orphan Drug Application for Treatmen .. of Atypical Hemolytic Uremic Syndrome with OMS721
[ Wed, Apr 17th 2013 ] - Market Wire
Lorus Therapeutics Signs Research and License Option Agreement with Elanco
[ Wed, Apr 17th 2013 ] - Market Wire
VentriPoint Receives CE Mark for Major Expansion of Its VMST Platform for Right Heart Analysis
[ Wed, Apr 17th 2013 ] - Market Wire
Stem Cell Therapeutics Licenses Exclusive Rights to Clinical Cancer Stem Cell Program
[ Wed, Apr 17th 2013 ] - Market Wire
Syneron Medical Appoints Co-Founder and Chairman .. Board Shimon Eckhouse to Chief Executive Officer
[ Wed, Apr 17th 2013 ] - Market Wire
Quest Diagnostics to Acquire Lab-Related Clinical .. ations of Dignity Health in California and Nevada
[ Wed, Apr 17th 2013 ] - Market Wire
CML HealthCare Inc. Appoints Chief Medical Officer
[ Wed, Apr 17th 2013 ] - Market Wire
Almirall und Forest Laboratories geben positive R .. zur Kombination von Aclidinium und Formoterol be
[ Wed, Apr 17th 2013 ] - Market Wire
Almirall e Forest Laboratories annunciano i risul .. i fase III per la combinazione aclidinium e formo
Tue, April 16, 2013
[ Tue, Apr 16th 2013 ] - Market Wire
Quest Diagnostics Names Jim Davis, Senior Vice President, Diagnostic Solutions
[ Tue, Apr 16th 2013 ] - Market Wire
BioScrip Announces Proposed Refinancing of Existing Indebtedness
[ Tue, Apr 16th 2013 ] - Market Wire
BioScrip Announces Proposed Public Offering of Common Stock
[ Tue, Apr 16th 2013 ] - Market Wire
Actavis Confirms Favorable Ruling in Generic Yaz Patent Suit
[ Tue, Apr 16th 2013 ] - Market Wire
Rochester Medical Announces Second Quarter 2013 Earnings Conference Call Thursday, April 25, 2013

Rochester Medical Announces Second Quarter 2013 Earnings Conference Call Thursday, April 25, 2013


Published on 2013-04-16 11:45:26 - Market Wire
  Print publication without navigation


Rochester Medical Announces Second Quarter 2013 Earnings Conference Call Thursday, April 25,... -- STEWARTVILLE, Minn., April 16, 2013 /PRNewswire/ --

[ ]

[ Download image ]

STEWARTVILLE, Minn., April 16, 2013 /PRNewswire/ -- Rochester Medical Corporation (NASDAQ: [ ROCM ]) will announce quarterly results after financial markets close on Thursday, April 25th, 2013.  The Company will then hold a quarterly conference call Thursday, April 25th, 2013 to discuss its earnings report.  The call will begin at 3:30 p.m., central time (4:30 p.m., Eastern Time).

(Logo: [ http://photos.prnewswire.com/prnh/20121228/CG34999LOGO ])

This call is being webcast by Thomson Reuters and can be accessed at Rochester Medical's website at [ www.rocm.com ].  To listen live to the conference call via telephone, call:

Domestic: 

888 679 8018

International:

617 213 4845

Pass code:

69140545

Pre Registration:
[ https://www.theconferencingservice.com/prereg/key.process?key=PFY3WDB6C ]


Replay will be available for seven days at [ www.rocm.com ] or via telephone at:

Domestic:

888 286.8010

International:

617 801.6888

Pass code:

48212906

Rochester Medical Corporation develops, manufactures, and markets disposable medical catheters and devices for urological and continence care applications.  The Company also sells certain ostomy and wound and scar care products and other brands of urological products into the European marketplace.

For further information, please contact Anthony J. Conway , President and Chief Executive Officer or David A. Jonas , Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600.  More information about Rochester Medical is available on its website at [ http://www.rocm.com ].

SOURCE Rochester Medical Corporation



RELATED LINKS
[ http://www.rocm.com ]
Contributing Sources